Table 4. Cox proportional hazards regression analysis of overall and disease-free survival from any cause associated with BMI among non-metastatic colorectal cancer patients (n = 1069).
BMI (kg/m2) | Overall Survival | Disease-free Survival | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Multivariable* | Multivariable** | Multivariable* | Multivariable** | |||||||||
HR | 95%CI | P | HR | 95%CI | P | HR | 95%CI | P | HR | 95%CI | P | |
<18.5 | 0.839 | 0.303–2.323 | 0.736 | 0.890 | 0.708–1.119 | 0.319 | 0.942 | 0.781–1.136 | 0.530 | 0.935 | 0.756–1.155 | 0.531 |
18.5–24.9 | 0.793 | 0.700–0.899 | <0.001 | 0.808 | 0.703–0.930 | 0.003 | 0.821 | 0.732–0.920 | 0.001 | 0.836 | 0.737–0.949 | 0.006 |
25–30 | 1.194 | 0.925–1.540 | 0.173 | 1.197 | 0.879–1.630 | 0.254 | 1.117 | 0.875–1.426 | 0.373 | 1.170 | 0.869–1.575 | 0.301 |
>30 | 0.937 | 0.744–1.178 | 0.576 | 1.182 | 0.678–2.061 | 1.182 | 0.947 | 0.770–1.165 | 0.605 | 1.189 | 0.815–1.735 | 0.368 |
MetS = metabolic syndrome, CRC = colorectal cancer, HR = hazard ratio, CI = confidence interval.
Adjusted for MetS.
Adjusted for all covariates (age, gender, MetS, TNM staging, differentiation, high density lipoprotein, uric acid, carcinoembryonie antigen).